文献速递病毒性肝炎艾滋病与性传播感染细菌感染、耐药与抗菌药物

肯尼亚注射吸毒人群中丙型肝炎的流行率、估算发病率、危险行为与基因型分布

Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
PubMed 文献 · Lancet Infect Dis · 2019-09-17

该回顾性队列研究在肯尼亚三个地区通过针具交换项目招募2188名注射吸毒者,抗-HCV阳性率为13%,沿海地区最高(22%)。

要点

  • 肯尼亚注射吸毒者抗-HCV阳性率13%,沿海地区达22%,西部仅1%
  • 抗-HCV阳性者中81%为病毒血症,基因型以1a(51%)和4a(47%)为主

核心结论

  • 肯尼亚注射吸毒人群中HCV流行率、估算发病率和危险行为存在地区差异,沿海地区估算发病率最高。

研究设计与样本

  • 回顾性队列研究,在肯尼亚内罗毕、沿海和西部地区的针具交换项目点采用应答者驱动抽样招募2188名18岁以上有注射吸毒史者。
  • 参与者接受抗-HCV筛查,阳性者行HCV RNA确认检测,可检测到HCV RNA者进行基因分型,并通过访谈收集肠外危险行为和服务暴露信息。

主要发现

  • 2188名参与者中291名(13%)抗-HCV阳性:沿海183/842(22%)、内罗毕105/817(13%)、西部3/529(1%)。
  • 284名抗-HCV阳性者成功行HCV RNA检测,其中230名(81%)存在病毒血症。
  • HIV阳性参与者中HCV流行率:沿海50%(66/131)、内罗毕35%(42/121)、西部4%(1/23)。
  • 主要基因型为1a(51%)、4a(47%)和混合型(2%;三例1a/4a和一例1a/2b)。

关键数值与推荐

  • 沿海地区与HCV风险增加相关的因素包括监禁史、注射年限更长、过去一个月注射次数更多和接受性共用炊具。
  • 内罗毕与HCV风险相关的因素包括女性、注射年限更长、过去一个月注射次数更多和经常使用可拆卸针头注射器。
  • HIV-HCV共感染的危险因素与HCV单一感染相似。

临床怎么用

  • 研究结果可用于指导针对性策略以减少HCV传播,如扩大针具交换项目、扩大阿片类激动剂治疗和在高风险地区实施治疗即预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sub-Saharan Africa has a large population of people with hepatitis C virus (HCV) infection, yet little is known about HCV among people who inject drugs this region. We assessed the prevalence of HCV mono-infection and HIV-HCV co-infection, and the estimated incidence, genotypes, and risk behaviours associated with HCV among people who inject drugs in Kenya. METHODS: People aged 18 years or older who were living in Nairobi, coastal Kenya, or western Kenya, had a history of injection drug use, and had used any illicit drugs in the past 12 months were recruited at needle and syringe programme sites using respondent-driven sampling. Participants were screened for the presence of an anti-HCV antibody. Those who were anti-HCV positive underwent confirmatory HCV RNA testing, and those with detectable HCV RNA were genotyped. Participants were interviewed regarding parenteral risk behaviours and exposure to services received at the needle and syringe programme sites. We examined correlates of HCV infection and HIV-HCV co-infection using bivariate and multivariate regression, and estimated HCV incidence. FINDINGS: Of 2188 enrolled participants, 291 (13%) were anti-HCV positive: 183 (22%) of 842 participants in coastal Kenya, 105 (13%) of 817 in Nairobi, and three (1%) of 529 in western Kenya. 284 anti-HCV-positive participants underwent successful HCV RNA testing, of whom 230 (81%) were viraemic. Estimated incidence rates of anti-HCV positivity per 100 person-years were 6·31 in coastal Kenya, 3·19 in Nairobi, and 0·22 in western Kenya. HCV incidence rate was greater in coastal Kenya compared with Nairobi (incidence rate ratio 1·97 [95% CI 1·35-2·93], p=0·0001) and the western region (28·17 [7·55-236·58], p<0·0001). In the coastal region, history of incarceration, more years injecting, more injections in the past month, and receptive cooker sharing were associated with increased risk of HCV, while female sex, more years injecting, more injections in the past month, and regular use of a syringe with a detachable needle were associated with HCV risk in Nairobi. HCV prevalence among HIV-positive participants was 50% (66 of 131 participants) in coastal Kenya, 35% (42 of 121) in Nairobi, and 4% (one of 23) in western Kenya. Risk factors for HIV-HCV co-infection were similar to those observed for HCV mono-infection. The prevailing genotypes were 1a (51%), 4a (47%), and mixed (2%; three 1a/4a and one 1a/2b). INTERPRETATION: HCV prevalence, estimated incidence, and risk behaviours among people who inject drugs in Kenya vary with region, with the highest estimated incidence observed in coastal Kenya. These findings should be used to inform focused strategies to reduce HCV transmission, such as expansion of needle and syringe programmes, upscaling of opioid agonist therapy, and treatment as prevention in regions affected by injection drug use and HCV. FUNDING: National Institute on Drug Abuse.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Akiyama MJ, Cleland CM, Lizcano JA, et al. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. Lancet Infect Dis. 2019. PMID: 31540840. doi:10.1016/S1473-3099(19)30264-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。